Enanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2M

Enanta Pharmaceuticals reported FY2026 revenue of $63.0M, down from $65.3M in FY2025, and a net loss of $68.2M, or $2.35 per share, improving from a $81.9M loss in FY2025. The company had $194.5M in cash and expects funding into fiscal 2029. Key catalysts include Q1 2027 LOTUS topline data and 2027 RESOLVE Phase 2b results.

Original reporting
Published Nov 16, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Enanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2M — source image
Decision brief

The 30-second read

$ENTABearishMed
01

Why it matters

The FY2026 financials and cash runway update the company-specific risk profile. The next tradable catalysts are scheduled clinical readouts (Q1 2027 LOTUS topline and 2027 RESOLVE Phase 2b), so this disclosure mainly affects positioning and financing/dilution expectations rather than immediate trial outcomes.

02

Market read

Traders can reassess ENTA’s near-term financing risk and valuation sensitivity ahead of later 2027 clinical milestones based on the reported loss and cash runway.

03

What to watch

The article does not quantify operating cash burn, cost structure drivers, or any updated probability of success for RSV programs, which could materially change how the market interprets the loss and runway.

Relevance 6/10Novelty 6/10Timing: after-hours/late-day disclosure, before next clinical catalysts (Q1 2027 LOTUS topline, 2027 RESOLVE Phase 2b)

Background

Enanta is described as a clinical-stage company with declining royalty revenue and an advancing pipeline toward later-stage RSV development.

Company-level read

Ticker impact

$ENTABearishMedium confidence
Context

Enanta reports FY2026 revenue of $63.0M and a net loss of $68.2M, plus cash of $194.5M and funding expected into fiscal 2029.

Expected impact

Likely downward pressure as investors weigh the larger net loss versus FY2025 and the implications for financing needs, partially offset by the stated funding runway into 2029.

Evidence & confidence

The article provides concrete financial datapoints (revenue, net loss, cash) and a runway statement, but it does not include new clinical trial results or guidance changes beyond the funding expectation.

Market effects

Reinforces typical biotech financing and burn-rate concerns for clinical-stage companies, especially those with royalty revenue decline.

No clear regional spillover beyond US small/mid-cap biotech sentiment.

Limited, as the disclosure is company-specific and not tied to a global macro or regulatory event.

Counterpoint

Investors may focus less on the net loss level and more on the narrowing loss trend and the stated funding runway into 2029, viewing the cash position as reducing near-term dilution risk.

Key entities

  • Enanta Pharmaceuticals

    Clinical-stage biotech reporting FY2026 revenue, net loss, cash balance, and expected funding into fiscal 2029.

Related articles

$ENTAMed

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 • Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q

$ENTAMed

Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court of the European Union against Pfizer Inc. and certain of its…

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability

$ENTAMed

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 • Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 • On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Ri

$ENTAMed

Enanta Was First To File. Pfizer Still Won. The Difference Was One Digit.

The US Federal Circuit affirmed that every claim in Enanta Pharmaceuticals’ patent on a coronavirus protease inhibitor is invalid in Enanta Pharmaceuticals, Inc. v. Pfizer Inc. (Fed. Cir. June 23, 2026). The court said Enanta’s provisional did not disclose the relevant C1 alkyl range, so Pfizer’s April 6, 2021 nirmatrelvir (Paxlovid) presentation was prior art. Paxlovid earned about $19B in 2022.